par Chuang, Wan Long;Hu, Tsung Hui;Buggisch, Peter;Moreno, Christophe 
;Su, Wei Wen;Biancone, Luigi;Camargo, Marianne;Hyland, Robert R.H.;Lu, Sophia;Kirby, Brian B.J.;Dvory-Sobol, Hadas;Osinusi, Anu A.O.;Gaggar, Anuj;Peng, Cheng Yuan;Liu, Chen Hua;Sise, Meghan M.E.;Mangia, Alessandra
Référence The American journal of gastroenterology, 116, 9, page (1924-1928)
Publication Publié, 2021-09-01
;Su, Wei Wen;Biancone, Luigi;Camargo, Marianne;Hyland, Robert R.H.;Lu, Sophia;Kirby, Brian B.J.;Dvory-Sobol, Hadas;Osinusi, Anu A.O.;Gaggar, Anuj;Peng, Cheng Yuan;Liu, Chen Hua;Sise, Meghan M.E.;Mangia, AlessandraRéférence The American journal of gastroenterology, 116, 9, page (1924-1928)
Publication Publié, 2021-09-01
Article révisé par les pairs
| Résumé : | INTRODUCTION: We evaluated 8, 12, or 24 weeks of ledipasvir/sofosbuvir in patients with hepatitis C virus and end-stage renal disease undergoing dialysis. METHODS: Primary efficacy end point was sustained virologic response 12 weeks after treatment. Primary safety end point was treatment discontinuation because of adverse events (AEs). RESULTS: Ninety-four percent (89/95) achieved sustained virologic response 12 weeks after treatment. Six patients died during treatment (n = 4) or before study completion (n = 2); no deaths were related to treatment. No patients discontinued treatment because of AEs. Thirteen percent had serious AEs; none were related to treatment. DISCUSSION: Treatment with ledipasvir/sofosbuvir was safe and effective in patients with end-stage renal disease undergoing dialysis. |
